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Acute infectious mononucleosis (AIM) is a widespread viral disease that
mostly affects children. Development of AIM is accompanied by a change in the
ratio of immune cells. This is provided by means of different biological processes
including the regulation of apoptosis of naive T-cells. One of the potential regulators
of apoptosis of T-lymphocytes is a death receptor 3 (DR3). We have studied the role of
DR3 in the regulation of apoptosis of naive CD4+ (nTh) and CD8+ (nCTL) T-cells in
healthy children and children with AIM. In healthy children as well as in children with
AIM, the activation of DR3 is accompanied by inhibition of apoptosis of nTh. In
healthy children, the stimulation of DR3 resulted in the increase in apoptosis of nCTL.
On the contrary, in children with AIM, the level of apoptosis of nCTL decreased after
DR3 activation, which is a positive contribution to the antiviral immune response. In
children with AIM, nCTL are characterized by reduced level of apoptosis as compared
with healthy children. These results indicate that DR3 can be involved in the reduction
of sensitivity of nCTL to apoptosis in children with AIM.
Keywords: acute infectious mononucleosis, apoptosis, DR3, naive
T-lymphocytes
Introduction
Acute infectious mononucleosis (AIM) is a widespread viral disease. It is
characterized by life-long latent virus persistence and its intermittent reactivation
in a host. More than 90% of the urban population is infected, but an acute form of
the disease manifests in only 10% of them. Most often the disease develops in
childhood [1].
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AIM agents are Herpesviridae, a family of DNA viruses: Epstein–Barr virus
(EBV), cytomegalovirus (CMV), and human herpesvirus type 6. They are
lymphotropic viruses that can affect the functional state of the cells of the immune
system. In particular, they cause anergy of T-lymphocytes and regulate prolifera-
tion and apoptosis of immunocompetent cells [2].
It is shown that EBV is accompanied by a signiﬁcant increase in the number
of CD8+ cytotoxic T-lymphocytes in the peripheral blood [3, 4]. This subpopula-
tion of T-lymphocytes plays an important role in the antiviral immune response
both in the lytic and latent phases of AIM [5]. In people with insufﬁcient activation
of the CD8+ T-cells, the disease progresses fulminantly [6]. The amount of CD4+
T-lymphocytes in the peripheral blood in patients with AIM is kept at a constant
but at low level. With that CD4+ T-cells that are activated against virus, antigens
are found with high frequency in the peripheral blood of AIM patients [7, 8].
A sufﬁcient number of mature immunocompetent cells in peripheral blood
are maintained by preservation of the pool of naive T-cells that have proliferative
and differentiation potential [9]. In children, the maintenance of homeostasis of
T-cells may depend on the thymic output of fresh naive T-lymphocytes, as well as
on the proliferation or the death of resting and activated T-cells [10]. In patients
with chronic active AIM, a decrease in the content of a common pool of CD4+ and
CD8+ T-lymphocytes in the peripheral blood is detected, which is associated with
a poor prognosis [11]. Enhanced death of naive T-lymphocytes by apoptosis
potentially reduces the effectiveness of immune responses in patients with AIM.
The membrane death receptor 3 (DR3) is expressed on CD4+ and CD8+
T-lymphocytes. In vivo DR3 realizes its function through binding to the natural
ligand. In vitro DR3 activation may be initiated with addition of monoclonal
antibodies or recombinant ligand [12]. DR3 takes part in the activation of
apoptosis and proliferation trigger events, as well as in the regulation of the
immune response [13, 14]. At present, DR3 is considered to have mainly a
proliferative activity in peripheral T-lymphocytes [15, 16]. However, this receptor
is also involved in negative selection of pre-T-cells in the thymus and initiates the
apoptosis following the ligand stimulation [17]. Thus, DR3 signaling may be
involved in the regulation of lymphocyte homeostasis by modulating either cell
death or lymphocyte activation.
The functional role of DR3 in the immunopathogenesis of AIM has not been
studied enough. It is shown that mice that do not express DR3, are more susceptible to
CMV infection due to insufﬁcient activation ofCD8+T-lymphocytes [18]. InAIM, the
participation of DR3 in apoptosis of naive T-cells remains unresolved.
The aim of this study was to estimate the relation of DR3 with apoptosis
of naive CD4+ (nTh) and naive CD8+ (nCTL) T-lymphocytes in children
with AIM.
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Materials and Methods
Subjects
The study complies with the Declaration of Helsinki [adopted in June, 1964
(Helsinki, Finland) and revised in October, 2000 (Edinburg, Scotland)] and was
approved by the Ethics Committee of Nizhny Novgorod State Medical Academy.
Peripheral blood was obtained from children at the age of 9–16 years. Parents or
guardians of participants gave written informed consent. Two groups were
formed: healthy children (n= 38) and children diagnosed with acute infection
mononucleosis (n= 34).
Cell isolation and puriﬁcation
Human peripheral blood mononuclear cells were isolated from fresh whole
blood by density gradient centrifugation using Histopaque (ρ= 1.077 g/cm3, Sigma,
USA). The subpopulations of nTh (CD4+CD45RO−) and nCTL (CD8+CD45RO−)
were isolated by negative magnetic immunoseparation using commercial kits series
EasySep (Stemcell Technologies, UK). The purity of isolated cells was monitored
by ﬂow cytometry using a panel of ﬂuorescent-labeled mAb: CD3-PE, CD45RO-
PE-Cy7, CD45RA-PerCP-Cy5.5, and CD8-APC-eFluor780 (or CD4-APC-
eFluor780) (eBioscience, USA). We veriﬁed that the subpopulations of nTh and
nCTL T-cells were puriﬁed to more than 98% (Figure 1).
Cultivation and activation of naive T-lymphocytes
The isolated T-cell subpopulations were cultured separately at a concentration
of 1× 106 cells/ml in RPMI-1640 medium (PanEco, Russia) and supplemented with
10% fetal calf bovine serum (PAA Laboratories, Austria) and 2 mM L-glutamine at
37 °C and 5% CO2. Speciﬁc receptor DR3 activation was performed with mouse
anti-human anti-DR3 mAb (clone JD3, isotypeIgGk, eBioscience, USA) in con-
centration 200 ng/ml. Control naive T-cells were cultivated with addition of
phosphate-buffer saline.
Flow cytometry
All samples were analyzed using a BD FACS Canto II multicolor ﬂow
cytometer (Becton, Dickinson and Company, USA). Cytometry setup and tracking
beads (BD Biosciences, USA) were used to initialize photomultiplier tubes’ settings.
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Figure 1. Control of naive CD4+ (a–c) and naive CD8+ (d–f) T-lymphocytes isolation purity by ﬂow
cytometry. Based on direct and side scatters, we separated debris and isolated lymphocyte gate (a, d);
in an isolated gate, we analyzed the expressions of CD3 and CD4 (b) or CD3 and CD8 (e) markers,
the content of CD3+CD4+ or CD3+CD8+ lymphocytes being over 99%; in CD3+CD4+ or
CD3+CD8+ lymphocyte pools, we studied the expression of CD45RA and CD45RO markers (c, f),
the content of CD45RA+CD45RO− cells being over 99%. The resulting content of naive CD4+ or
naive CD8+ T-lymphocytes was over 98%
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Anti-mouse Ig, k/negative control compensation particles set (BD Biosciences, USA)
was used to optimize ﬂuorescence compensation settings. In each sample, 30,000
cells were acquired. For the ﬂuorescent-labeled mAb, the gate settings were
established using the relevant isotype controls. All data are acquired electronically
in the BD FACS Diva 6.1.3 software (BD Biosciences, USA).
DR3 expression analysis and apoptosis assay
Apoptosis and DR3 expression assay were performed using ﬂow cytometry.
We analyzed freshly isolated nTh, nCTL, and cells after 24 h of culture with or
without anti-DR3 mAb (anti-DR3 mAb treated and control cells). To assess the level
of apoptosis, we employed double staining with Annexin V-PE (AV) and
7-aminoactinomycin-D (7AAD) using a commercial kit “PE Annexin V Apoptosis
Detection Kit” (BD Biosciences, USA). DR3 expression on the membrane of live and
apoptotic naive lymphocytes was analyzed using ﬂuorescently labeled mAb DR3-
DyLight 488 (Novus Biological, USA). The percentage of live cells and cells in early
and late stages of apoptosis, i.e., the percentage of DR3-negative and DR3-positive
cells, was calculated using the total number of T-lymphocytes (Figure 2). The density
of the membrane expression of DR3 was evaluated based on the mean ﬂuorescence
intensity (MFI) of DR3-positive cells.
Data processing
Two groups of normally distributed data were compared using an independent
sample t-test or dependent t-test for paired samples, and the difference among
multiple groups was analyzed using two-way analysis of variance (ANOVA). A
Wilcoxon rank-sum test for independent or dependent paired samples was performed
to analyze the difference between two groups of non-normally distributed data, and
the Friedman test was performed to compare the differences among multiple groups.
Mixed-effect linear regression analysis was performed to investigate the relationship
between the measured quantitative variables and the treatment of naive T-cells. The
p values for multiple comparisons were adjusted using the Holm–Bonferroni
correction. p< 0.05 was considered statistically signiﬁcant. The presented p values
and the signiﬁcance threshold were two-sided. The difference between two groups
was expressed as 95% conﬁdence interval (CI, unsigned in the text and signed in the
illustrations). All statistical analyses were performed using R (version 3.1.1) in the
“RStudio 0.98.1098” shell [19, 20] with “stats,” “ﬂowCore,” “lawstat,” “multcomp,”
and “nlme” packages [21–25]. Illustrations were made using “ggplot2” package [26],
and quantitative variables were expressed as median and interquartile range.
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Figure 2. Gating principles when analyzing the apoptosis and expression level of DR3. Lymphocyte
gate was separated based on direct and side scatters (a); based on double AV and 7AAD staining,
lymphocytes were divided into live cells (solid line), early (dotted line), and late (dash line) apoptotic
cells (b); after that gates of live cells and cells in early stage of apoptosis were analyzed separately. In
each of them, the percentage of DR3− cells, DR3+ cells, and DR3 MFI was determined (c)
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Results
The content of live and apoptotic freshly isolated naive T-lymphocytes in healthy
children and children with AIM
It was shown that in freshly isolated nTh of healthy children, the percentage
of live cells was greater (CI= 10.76–19.79%, p< 0.001) and the percentages of
cells in early and late stages of apoptosis were lesser (CI= 2.34–5.51%, p= 0.005
vs. early apoptotic cells; CI= 5.34–8.08%, p= 0.016 vs. late apoptotic cells) than
in freshly isolated nCTL. In nTh of children with AIM, the percentage of live cells
and cells in early and late stages of apoptosis did not differ from nCTL (Figure 3).
Compared with healthy children, there was no change revealed in the
content of freshly isolated live nTh and nTh in early and late stages of apoptosis
in children with AIM. In nCTL of children with AIM, the percentage of cells in
late stage of apoptosis decreased (CI= 1.70–11.03%, p= 0.011), and the percent-
age of live nCTL and nCTL in early stage of apoptosis did not change as compared
with healthy children (Figure 3).
DR3 expression on the membrane of freshly isolated live and apoptotic naive
T-lymphocytes in healthy children and children with AIM
In general, regardless of the culture conditions in healthy children and
children with AIM, the surface density of DR3 expression was greater in naive
T-lymphocytes in early stage of apoptosis compared with live cells. In nTh of
children with AIM, the rise of DR3 MFI on early apoptotic cells was greater
compared with healthy children, especially in freshly isolated cells. Similar results
were obtained by comparing the live nCTL with nCTL in early stage of apoptosis:
in children with AIM, DR3 MFI on the early apoptotic cells increased to a greater
extent than in healthy children (Figure 4).
In healthy children, we revealed differences in the expression of DR3 in
freshly isolated nTh compared with nCTL. The percentage of live DR3− cells was
greater (CI= 13.72–24.00%, p< 0.001) in nTh and the percentage of live DR3+
cells was lesser (CI= 1.14–5.33%, p= 0.009) in nTh than in nCTL. The percent-
age of early apoptotic DR3− nTh did not differ, and the percentage of early
apoptotic DR3+ nTh decreased (CI= 1.65–3.30%, p< 0.001) compared with
nCTL. DR3 MFI on live and early apoptotic nTh was lesser (CI= 6.22–13.67,
p< 0.001 vs. live cells; CI= 3.17–839.57, p= 0.016 vs. cells in early stage of
apoptosis) than on nCTL (Figure 5).
In children with AIM, there was no difference revealed in DR3 expression
between freshly isolated nTh and nCTL
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In children with AIM, DR3 MFI was higher (CI= 110.58–381.66,
p= 0.002) on the membrane of freshly isolated nTh in early stage of apoptosis
compared with healthy children. No difference was found in DR3 MFI on the
membrane of early apoptotic cells and the percentage of DR3− and DR3+ live and
early apoptotic cells when comparing freshly isolated nTh in children with AIM
and healthy children (Figure 5).
In children with AIM, the percentage of live freshly isolated DR3− nCTL
increased (CI= 2.65–23.73%, p= 0.030) and the percentage of early apoptotic
DR3+ cells decreased (CI= 0.24–3.36%, p= 0.037) compared with healthy chil-
dren. DR3 MFI on the membrane of live nCTL was lesser (CI= 9.02–20.54,
Figure 3. The percentage of live and apoptotic naive T-lymphocytes in healthy children and
children with AIM.
* indicates statistically signiﬁcant difference (p< 0.05) compared with healthy children;
** indicates statistically signiﬁcant difference (p< 0.05) compared with nCTL
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p= 0.009) in children with AIM than in healthy children. No other difference was
found in DR3 expression when comparing freshly isolated nCTL in children with
AIM and healthy children (Figure 5).
DR3 impact on the content of live and apoptotic nTh in healthy children and
children with AIM
In healthy children with control and anti-DR3 mAb-treated nTh, the
percentage of live cells decreased (CI= 21.94–44.96%, p< 0.001 vs. control;
Figure 4. Density plot of DR3 expression on the membrane of live and early apoptotic naive
T-lymphocytes in healthy children and children with AIM. The 95% conﬁdence interval and p-value
for differences in mean levels of DR3 MFI between live and early apoptotic cells are shown
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Figure 5.DR3 expression on the membrane of naive T-lymphocytes in healthy children and children
with AIM. The percentage of DR3-negative (a), the percentage of DR3-positive (b) naive
T-lymphocytes, and DR3MFI (c) are shown. * indicates statistically signiﬁcant difference (p< 0.05)
compared with healthy children; ** indicates statistically signiﬁcant difference (p< 0.05) compared
with nCTL
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CI= 23.29–46.32%, p< 0.001 vs. anti-DR3 mAb-treated cells) compared with
freshly isolated nTh. The percentage of nTh in early stage of apoptosis did not
change but the percentage of cells in late stage of apoptosis increased (CI= 27.16–
49.07%, p< 0.001 vs. control; CI= 33.88–55.78%, p< 0.001 vs. anti-DR3 mAb-
treated cells) in both cases compared with freshly isolated cells (Figure 6a).
In control and anti-DR3 mAb-treated nTh, the decrease in the percentage of
live cells was a result of the decrease in the percentage of live DR3− cells
(CI= 22.66–42.46%, p< 0.001 vs. control; CI= 23.61–43.40%, p< 0.001 vs.
anti-DR3 mAb-treated cells), because the percentage of live DR3+ nTh did not
change as compared with freshly isolated cells (Figure 5a and b). Only in control
nTh, DR3 MFI on the membrane of live cells increased (CI= 1.01–5.76, p=
0.003) compared with freshly isolated cells; in anti-DR3 mAb-treated cells, DR3
MFI rate did not change (Figure 6c).
While the percentage of nTh in early stage of apoptosis did not change in anti-
DR3 mAb-treated cells, the percentage of early apoptotic DR3− nTh decreased
(CI= 0.91–9.10%, p= 0.012) compared with freshly isolated cells. No such change
was found in control cells (Figure 6b). We did not ﬁnd the difference in the
percentage of DR3+ nTh in early stage of apoptosis both in control and anti-DR3
mAb-treated cells compared with freshly isolated nTh. However, in both cases,
DR3MFI on the membrane of early apoptotic cells was greater (CI= 39.85–109.49,
p< 0.001 vs. control; CI= 26.18–95.73, p< 0.001 vs. anti-DR3 mAb-treated cells)
than in freshly isolated nTh (Figure 6b and c).
In children with AIM in control and anti-DR3 mAb-treated nTh, the
percentage of live cells decreased (CI= 3.14–34.34%, p= 0.010 vs. control;
CI= 4.90–36.11%, p= 0.006 vs. anti-DR3 mAb-treated cells) compared with
freshly isolated cells. In control nTh, the percentage of cells in early stage of
apoptosis did not change and that in anti-DR3 mAb-treated cells decreased (CI=
0.65–8.96%, p= 0.020) compared with freshly isolated cells. Both in control and
anti-DR3 mAb-treated nTh, the percentage of cells in late stage of apoptosis
increased (CI= 8.89–43.32%, p= 0.001 vs. control; CI= 12.62–47.05%, p< 0.001
vs. anti-DR3 mAb-treated cells) compared with freshly isolated cells (Figure 6a).
While the percentage of live nTh decreased, both in control and anti-DR3
mAb-treated cells, the percentage of live DR3− cells decreased (CI= 1.70–
33.41%, p= 0.019 vs. control; CI= 3.09–34.81%, p= 0.015 vs. anti-DR3
mAb-treated cells) and the percentage of live DR3+ cells did not change compared
with freshly isolated cells (Figure 6b). No change was found in DR3 MFI on the
membrane of live cells in both cases (Figure 6c).
In children with AIM, no difference was found in DR3 expression pattern in
early apoptotic cells between control and freshly isolated nTh. In anti-DR3 mAb-
treated cells, the percentage of nTh in early stage of apoptosis decreased as a result
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Figure 6. Differences in mean levels of the percentage of live and apoptotic naive T-cells (a), the
percentage of DR3-negative and DR3-positive naive T-cells (b), and DR3 MFI (c) 95% family-wise
conﬁdence level is shown
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of decreased percentage of early apoptotic DR3−cells (CI= 0.48–7.51%, p=
0.023) compared with freshly isolated cells. The percentage of DR3+ nTh in early
stage of apoptosis and DR3 MFI on their membrane did not change simulta-
neously (Figure 6b and c).
DR3 impact on the content of live and apoptotic nCTL in healthy children and
children with AIM
In healthy children in control and anti-DR3 mAb-treated cells, the percent-
age of live nCTL decreased (CI= 1.42–34.50%, p= 0.022 vs. control; CI= 7.61–
40.69%, p= 0.002 vs. anti-DR3 mAb-treated cells) compared with freshly isolated
cells. The percentage of nCTL in early stage of apoptosis also decreased (CI=
3.02–11.78%, p< 0.001 vs. control; CI= 4.76–13.52%, p< 0.001 vs. anti-DR3
mAb-treated cells), while the percentage of nCTL in late stage of apoptosis
increased (CI= 18.02–49.09%, p< 0.001 vs. control; CI= 25.23–56.31%, p<
0.001 vs. anti-DR3 mAb-treated cells) in both cases compared with freshly
isolated nCTL (Figure 6a).
In control nCTL, the decrease in the percentage of live cells was a result of
the decrease in the percentage of live DR3+ cells (CI= 1.81–8.52%, p< 0.001),
while the percentage of live DR3− cells did not change compared with freshly
isolated nCTL. In anti-DR3 mAb-treated nCTL, there was the decrease in the
percentage of both live DR3− and DR3+ cells (CI= 1.80–35.72%, p= 0.029 vs.
live DR3− cells; CI= 1.69–8.40%, p< 0.001 vs. live DR3+ cells) compared with
freshly isolated nCTL (Figure 6b). Both in control and anti-DR3 mAb-treated
nCTL, DR3 MFI on the membrane of live cells was lesser (CI= 4.08–14.31, p<
0.001 vs. control; CI= 4.78–15.01, p< 0.001 vs. anti-DR3 mAb-treated cells)
than on the membrane of freshly isolated nCTL (Figure 6b and c).
In both control and anti-DR3 mAb-treated nCTL of healthy children, the
decrease in the percentage of early apoptotic cells was a result of the decrease in
the percentage of DR3− cells in early stage of apoptosis (CI= 3.97–11.45%, p<
0.001 vs. control; CI= 3.53–11.01%, p< 0.001 vs. anti-DR3 mAb-treated cells)
compared with freshly isolated nCTL. No change was found in the percentage of
DR3+ nCTL in early stage of apoptosis or DR3 MFI on their membrane in both
cases compared with freshly isolated cells (Figure 6b and c).
In control and anti-DR3 mAb-treated cells of children with AIM, the
percentage of live nCTL decreased (CI= 0.72–30.78%, p= 0.046 vs. control;
CI= 0.96–30.53%, p= 0.046 vs. anti-DR3 mAb-treated cells) compared with
freshly isolated cells. The percentage of nCTL did not change in control and
decreased in anti-DR3mAb-treated cells (CI= 0.20–5.87%, p= 0.047) comparing
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with freshly isolated cells. In both cases, the percentage of nCTL in late stage of
apoptosis was greater (CI= 2.08–37.12%, p= 0.018 vs. control; CI= 6.44–
41.49%, p= 0.004 vs. anti-DR3 mAb-treated cells) than in freshly isolated nCTL
(Figure 6a).
In control nCTL, the decrease in the percentage of live cells was the result of
the decrease in the percentage of live DR3− cells (CI= 1.50–30.03%, p= 0.043),
while the percentage of live DR3+ cells did not differ as compared with freshly
isolated nCTL. On the contrary, in anti-DR3 mAb-treated cells, the percentage of
live DR3− cells did not change and the percentage of live DR3+ cells decreased
(CI= 0.12–4.95%, p= 0.042) compared with freshly isolated nCTL. DR3 MFI on
the membrane of live cells did not differ in both cases compared with freshly
isolated nCTL (Figure 6b and c).
In control nCTL of children with AIM, the percentage of DR3− and DR3+
cells in early stage of apoptosis did not differ from freshly isolated nCTL. In anti-
DR3 mAb-treated nCTL, the decrease in the percentage of cells in early stage of
apoptosis was the result of the decrease in the percentage of early apoptotic DR3−
cells (CI= 0.10–5.67%, p= 0.045), while the percentage of early apoptotic DR3+
cells did not change as compared with freshly isolated nCTL. In both cases, no
change was found in DR3 MFI on the membrane of nCTL in early stage of
apoptosis compared with freshly isolated cells (Figure 6b and c).
Discussion
In the literature data, the question of DR3 expression in T-cell subpopula-
tions still remains unclear. Jones et al. could not detect DR3 expression on resting
human Th, but activation with stimulatory anti-CD3 antibodies led to a marked up-
regulation of DR3. At the same time, Twohig et al. detected DR3 expression on
both murine Th and CTLs, and expression of the receptor was greater on Th
compared with CTLs [18, 27]. It was shown that resting human CD4+ or CD8+
T-cells express very little LARD-1 mRNA. LARD-1 is a full-length form of DR3
that has a transmembrane domain. Resting cells mainly express mRNA that codes
soluble forms of the protein, but LARD-1 expression dominates in phytohemag-
glutinin-activated cells [14].
We found that in both healthy children and children with AIM, DR3
expression on the surface of live freshly isolated nTh and nCTL was very low
or even absent (Figures 4 and 5). Apoptosis of naive T-lymphocytes was
accompanied by a dramatically increasing density of DR3 expression on their
surface. Thus, increased surface density of DR3 expression can be considered to
be a marker of apoptosis of naive T-lymphocytes.
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In healthy children, when apoptosis developed in control nTh, the percent-
age of live DR3− cells decreased and the percentage of live DR3+ nTh did not
change. The density of DR3 expression on the surface of live cells grew up. Thus,
among nTh, DR3− cells preferentially die by apoptosis, and the number of DR3+
nTh is maintained at a constant level. The same pattern was observed in anti-DR3
mAb-treated nTh, but in contrast to the control, there was no increase of DR3
expression detected on the membrane of live cells. Also DR3 stimulation led to
the reduction of the percentage of DR3− nTh in early stage of apoptosis, which
was not observed in the control. Meanwhile, the percentage of DR3+ early
apoptotic nTh did not change. We believe that live DR3-expressing nTh can
participate in the regulation of apoptosis of nTh that does not express this
receptor. As the result, in nTh, DR3 activation can inhibit proapoptotic activity of
DR3+ cells.
In healthy children in control nCTL, the growth of apoptosis was accom-
panied by the reduction of the percentage of live DR3+ cells. Meanwhile, the
percentage of live DR3−nCTL stayed the same. We suppose that in healthy
children, unlike nTh, among nCTL DR3-expressing cells can be more susceptible
to apoptosis than DR3-negative nCTL. In contradiction to control, in anti-DR3
mAb-treated nCTL, the percentage of both DR3− and DR3+ live cells decreased.
Thus, like in nTh, DR3+ nCTL can be capable of regulating the apoptosis of DR3−
cells. Unlike nTh, in nCTL DR3 function is opposite: DR3 activation can lead to
the enhancement of apoptosis of DR3− cells.
In healthy children, freshly isolated nCTL was characterized by the large
level of apoptosis, the low percentage of live DR3− cells, the high percentage of
live and early apoptotic DR3+ cells and the high DR3 MFI compared with freshly
isolated nTh. After 20 h of cultivating of isolated nCTL, we found out that the
percentage of live DR3+ and early apoptotic DR3− cells and the level of apoptosis
of nCTL went down to values of nTh (Figures 3 and 5). The results suggest that in
healthy children, a large amount of DR3+ cells and their enhanced activity can
cause the high level of apoptosis of nCTL compared with nTh. We speculate that
the apoptosis of nCTL in vivo can be regulated by elements of cellular microen-
vironment by means of DR3 activation. We also assume that DR3-mediated
regulation of apoptosis can be more typical for nCTL than for nTh.
According to the literature data, DR3 stimulation, as well as its over-
expression, causes spontaneous apoptosis in cell lines of T-lymphocyte origin
[14, 28]. In our study, the stimulation of naive T-lymphocytes with anti-DR3 mAb
did not lead to the change in the percentage of apoptotic cells compared with
control (Figures 3 and 6a). The absence of signiﬁcant changes in the level of
apoptosis may be due to the paucity of DR3+ cells and the population composition
of T-lymphocytes.
DR3 REGULATION OF APOPTOSIS 353
Acta Microbiologica et Immunologica Hungarica 63, 2016
Like in healthy children, in children with AIM, the apoptosis of nTh was
accompanied by the reduction of the percentage of live DR3− cells, while the
percentage of live DR3+ nTh did not change. Also, like in healthy children, we
detected the decrease in the percentage of early apoptotic DR3− cells in anti-DR3
mAb-treated nTh, but not in control cells. We suppose that, like in healthy
children, in children with AIM, DR3+ nTh can participate in the regulation of
apoptosis of DR3− nTh and DR3 activation can lead to the inhibition of the
apoptosis of nTh. Therefore, the DR3 function as a regulator of apoptosis of nTh
did not change in children with AIM.
Unlike healthy children, in children with AIM, the apoptosis of control
nCTL was accompanied by the decrease in the percentage of live DR3− cells,
while the percentage of live DR3+ nTh stayed at a constant level. DR3 activation
gave the opposite effect: the percentage of live DR3+ nCTL decreased, while the
percentage of live DR3− cells did not change. Besides that, addition of anti-DR3
mAb resulted in a decrease in the percentage of nCTL in early stage of apoptosis
by reducing the amount of early apoptotic DR3− cells. Thus, in children with AIM,
the stimulation of nCTL with anti-DR3 mAb led to the preferential loss of DR3+
cells while reducing the apoptosis of DR3− nCTL. We assume that in both healthy
children and children with AIM, DR3+ nCTL can enhance the apoptosis of DR3−
cells. However, in children with AIM, DR3 activation can initiate the apoptosis of
DR3+ nCTL, which in its turn causes the softening of their proapoptotic inﬂuence
on the other cells.
In children with AIM, no difference was found in the level of apoptosis or
DR3 expression pattern between freshly isolated nTh and nCTL. In children with
AIM, the level of apoptosis of freshly isolated naive T-lymphocytes did not differ
in nTh but was low in nCTL compared with healthy children. Also in children with
AIM, the percentage of live DR3− cells did not differ in nTh but was greater in
nCTL than in healthy children (Figures 3 and 5). DR3 function in the regulation of
apoptosis of naive T-lymphocytes did not change in children with AIM: DR3
activation inhibits apoptosis of nTh and enhances apoptosis of nCTL. However, in
children with AIM, the enhanced susceptibility of regulatory live DR3+ nCTL to
DR3-mediated apoptosis resulted in a signiﬁcant reduction of the apoptosis of the
total pool of nCTL compared with healthy children.
It is shown that, depending on the conditions and the type of cell, the
activation of death receptors can lead to a cell proliferation and an activation of
inﬂammatory reactions as well as an initiation of apoptosis. Signaling outcome
depends on the type of ligand, the set of adapter proteins and signaling systems,
and the internalization of the receptor as an important event in the process of
outcome regulation [29]. According to our data, DR3 was able to regulate the
apoptosis of naive T-lymphocytes both in healthy children and in children with
354 FILATOVA ET AL.
Acta Microbiologica et Immunologica Hungarica 63, 2016
AIM. In healthy children, DR3 activation led to increased apoptosis of nCTL and
in children with AIM, on the contrary, to its suppression. In nTh, both in healthy
children and children with AIM, DR3 exhibits anti-apoptotic properties. DR3-
mediated regulation of apoptosis of naive T-lymphocytes in children with AIM
can be considered as one of the mechanisms of changing the CD4/CD8
T-lymphocytes ratio toward the signiﬁcant increase in virus-speciﬁc CD8+
T-cells [30]. Thus, DR3 can play a signiﬁcant role in increasing the amount of
cytotoxic T-lymphocytes and thus in the elimination of the virus.
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